Castle Hook Partners’s Carisma Therapeutics CARM Stock Holding History

Castle Hook Partners’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-63,146	Closed	-$1.3M	–	37
2019 Q1	$1.3M	Buy	63,146 +12,500	+25%	+$216K	0.07%	48
2018 Q4	$1.44M	Hold	50,646	–	–	0.19%	37
2018 Q3	$2.18M	Hold	50,646	–	–	0.06%	53
2018 Q2	$1.98M	Buy	+50,646	New	+$2.23M	0.07%	52

Other funds holding CARM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

Castle Hook Partners's CARM Position: Q2 2019 in Review

Castle Hook Partners sold out of Carisma Therapeutics (CARM) in Q2 2019, closing a stake of 63,146 shares — an estimated $1.3M sold.

Castle Hook Partners first reported a position in CARM in Q2 2018 and held it in 4 quarters. The position peaked at $2.18M in Q3 2018. 43 funds tracked by Wall St. Rank hold CARM as of Q2 2019.

Castle Hook Partners reported no remaining Carisma Therapeutics position as of Q2 2019 after selling out during the quarter.
Castle Hook Partners sold 63,146 Carisma Therapeutics shares in Q2 2019, an estimated $1.3M.
Castle Hook Partners first reported a position in Carisma Therapeutics in Q2 2018 and held it in 4 quarters.
Castle Hook Partners's Carisma Therapeutics position peaked at $2.18M in Q3 2018.
43 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2019.

Based on Castle Hook Partners's 13F filing for Q2 2019, filed 14 Aug 2019.